Ally Prebtani

Ally Prebtani

Auto-generated profile, based on publicly available information

Ally Prebtani

Département de médecine (Manialawy, Yang, Prebtani) et Division d'endocrinologie et de métabolisme (Yang, Prebtani), McMaster University, Hamilton, Ont.

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 February 2025 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
AKAliya A. Khan
Aliya A. Khan
HAHajar AbuAlrob
Hajar AbuAlrob
DADalal Ali
Dalal Ali
ZKZayd Al Kassem
Zayd Al Kassem
AAAbdulrahman Almoulia
Abdulrahman Almoulia
BWBlandine Weiss
Blandine Weiss
Summary: In the CNHR study, 35% of postmenopausal women had osteoporosis by BMD or fragility fracture, and 4% had both. Three men ≥ 50 had osteoporosis by BMD or fragility fracture (33.3%; n = 3/9). This suggests that close follow-up of skeletal health is necessary in postmenopausal women, and men ≥ 50 with chronic HypoPT. Purpose: Chronic hypoparathyroidism (HypoPT) has been associated with decreased bone turnover and abnormalities in bone mineral density (BMD), microarchitecture, and strength. Current guidelines do not recommend systematic evaluation of skeletal health in patients with chronic HypoPT. Our study assessed skeletal health in pre- and postmenopausal women with chronic HypoPT and adult men. Methods: This prospective study enrolled adults with chronic HypoPT from the Canadian National Hypoparathyroidism Registry. Clinical characteristics, bone fractures, biochemistry, and serum bone biomarkers were assessed at baseline. Skeletal health evaluation included assessments of fragility fractures, BMD at lumbar spine (LS), femoral neck (FN), total hip (TH), 1/3 radial sites, trabecular bone score (TBS), and bone biomarkers. Results: We present the baseline data of the patients enrolled in the registry. We analyzed a total of 101 patients: 18 men, 35 premenopausal, and 48 postmenopausal women. The mean (SD) age at the onset of HypoPT was 40.7 (16.8) years, and the average disease duration was 11.2 (8.6) years. The most common etiology was postsurgical (74.3% vs. 25.7% non-surgical). Most patients received calcium supplements (89%) and active vitamin D (80%) at baseline. No fragility fractures or low BMD were reported in premenopausal women. However, BMD at LS, FN, TH, and TBS were significantly lower in postmenopausal compared to premenopausal women. Conclusions: Overall, 35% of postmenopausal women had osteoporosis by BMD or prior fragility fracture, and 4% had both. Three men ≥ 50 years had osteoporosis by BMD or fragility fracture (33.3%; n = 3/9). This study suggests that close follow-up of skeletal health is necessary in postmenopausal women with chronic HypoPT and men ≥ 50 years.

14 August 2024 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
BLBrian Lauzon
Brian Lauzon
TATala Abu-Hijleh
Tala Abu-Hijleh
NMNatalia McInnes
Natalia McInnes
APAlly Prebtani
Ally Prebtani
Hematologic malignancies are rare causes of sellar masses and hypopituitarism. We report 2 cases of hypopituitarism due to sellar masses from hematologic malignancies. The first patient was found to have hypopituitarism but initial non-gadolinium-enhanced magnetic resonance imaging (MRI) sella did not demonstrate a mass. Subsequent gadolinium-enhanced MRI and transsphenoidal biopsy confirmed a diagnosis of intravascular lymphoma. Treatment with systemic chemotherapy resulted in resolution of abnormalities on MRI. The second patient had a known diagnosis of chronic lymphocytic leukemia, and sellar involvement contributing to hypopituitarism was confirmed on biopsy. Treatment with ibrutinib, acalabrutinib, and stereotactic radiosurgery resulted in resolution of abnormalities on MRI. Both patients were treated with hormone replacement for hypopituitarism. These cases highlight that hematologic malignancies should be suspected as causes of sellar masses/hypopituitarism in patients with concurrent symptoms atypical for a pituitary adenoma (eg, constitutional symptoms), known diagnoses of hematologic malignancies, or rapid tumor growth and invasion on imaging. Gadolinium-enhanced MRI should be pursued if nonenhanced MRI is nondiagnostic. Transsphenoidal biopsy can be considered for diagnosis. Malignancy-directed systemic therapy may improve hypopituitarism and radiographic abnormalities on MRI.

23 August 2026 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
YMYousef Manialawy
Yousef Manialawy
YYYifan Yang
Yifan Yang
APAlly P.H. Prebtani
Ally P.H. Prebtani


10 May 2026 in Canadian Medical Association Journal
Verified
Journal Article
Open access
YMYousef Manialawy
Yousef Manialawy
YYYifan Yang
Yifan Yang
APAlly P.H. Prebtani
Ally P.H. Prebtani